Compare IDT & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDT | SLS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1996 | 2007 |
| Metric | IDT | SLS |
|---|---|---|
| Price | $77.30 | $19.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | 128.6K | ★ 10.8M |
| Earning Date | 12-03-2026 | 11-12-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | 14.95 | ★ 50.00 |
| EPS | ★ 3.46 | N/A |
| Revenue | ★ $1,231,495,000.00 | N/A |
| Revenue This Year | $2.39 | N/A |
| Revenue Next Year | $0.75 | N/A |
| P/E Ratio | $22.47 | ★ N/A |
| Revenue Growth | ★ 2.13 | N/A |
| 52 Week Low | $46.48 | $1.39 |
| 52 Week High | $84.56 | $24.89 |
| Indicator | IDT | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 77.39 |
| Support Level | $51.16 | $11.40 |
| Resistance Level | $84.48 | N/A |
| Average True Range (ATR) | 2.14 | 1.63 |
| MACD | -0.86 | 1.10 |
| Stochastic Oscillator | 14.00 | 70.00 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.